|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hinweise |
|
|
|
Wiss. Komitee |
|
|
|
Adressen |
|
|
|
Presse |
|
|
|
Öffnungszeiten |
|
|
|
Gesellschaften |
|
|
|
Hotelreservierung |
|
|
|
Termine |
|
|
|
Rahmenprogramm |
|
|
|
Gebühren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Online-Anmeldung
Online-Abstracts
Kontakt-Adressen
Congress Center Leipzig
zurück zum Start
Programm-Schwerpunkte-Gesellschaften
|
Symposium 23a Virale Hepatitis |
||
|
12.00 – 13.30 |
Vorsitz M.P. Manns; Hannover, B.R. Ruf; Leipzig |
|
|
Level 2– Raum 11 |
|
|
|
04.05.2001 |
Sy 23a.01 |
Pegylierte Interferone bei chronischer Hepatitis C |
|
12.00 |
H. Wedemeyer; Hannover |
|
|
Sy 23a.02 |
Prädiktive Marker für den Therapieerfolg |
|
|
12.25 |
C. Sarrazin; Frankfurt/Main |
|
|
Sy 23a.03 |
entfällt |
|
|
12.50 |
|
|
|
Sy 23a.04 |
Therapeutische Vakzinierung – aktueller Stand |
|
|
13.10 |
M. Geissler; Freiburg |
|
|
Mit freundlicher Unterstützung durch Essex Pharma |
||